1-(3-Ethylpyrrolidin-1-yl)propan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(3-Ethylpyrrolidin-1-yl)propan-1-one
• 英文别名: 1-(3-ethylpyrrolidin-1-yl)propan-1-one
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: XTQGZVDVPBAKBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS AGONISTES DU RÉCEPTEUR D3; PROCÉDÉS DE PRÉPARATION; INTERMÉDIAIRES DE CEUX-CI; ET LEURS PROCÉDÉS D'UTILISATION
  申请人：US HEALTH

  公开号：WO2020210785A1

  公开（公告）日：2020-10-15

  Disclosed herein are novel compounds including dopamine D3 receptor agonists, compositions thereof, methods of use thereof, and processes of synthesizing the same. Further disclosed are D3R selective agonist compounds, specifically bitopic ligands comprising chirality.

  本文披露了包括多巴胺D3受体激动剂在内的新颖化合物、其组合物、使用方法以及合成这些化合物的方法。进一步披露了D3R选择性激动剂化合物，具体包括具有手性的双位点配体。
• [EN] COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS<br/>[FR] COMPOSÉS CONTENANT UN GROUPE SULFONIQUE EN TANT QU'INHIBITEURS DE KAT
  申请人：EPIZYME INC

  公开号：WO2018102419A1

  公开（公告）日：2018-06-07

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、其药用可接受的组合物以及使用相同的方法。
• PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
  申请人：Genentech, Inc.

  公开号：US20150152117A1

  公开（公告）日：2015-06-04

  A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

  公式I的化合物、对映异构体、二对映异构体、互变异构体或其药学上可接受的盐，其中R1、R2和R3如本文所定义，可用作一个或多个Janus激酶的抑制剂。本发明还涉及一种包括公式I化合物和药学上可接受的载体、辅料或溶剂的制药组合物，以及治疗或减轻患者对Janus激酶活性抑制有反应的疾病或病情的方法。
• MACROCYCLES AS FACTOR XIA INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150266894A1

  公开（公告）日：2015-09-24

  The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或fXIa和血浆卡利肯酶的双重抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞性和/或炎症性疾病的方法。
• THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES
  申请人：Dana-Farber Cancer Institute

  公开号：EP3715346A1

  公开（公告）日：2020-09-30

  The present disclosure provides thiazolyl-containing compounds of Formula (II). The compounds described herein may be able to inhibit protein kinases (e.g., Src family kinases (e.g., hemopoietic cell kinase (HCK)), Bruton's tyrosine kinase (BTK)) and may be useful in treating and/or preventing proliferative diseases (e.g., myelodysplasia, leukemia, lymphoma (e.g., Waldenstrom's macroglobulinemia)) and in inducing apoptosis in a cell (e.g., malignant blood cell). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

  本公开提供了式(II)的含噻唑化合物。本文所述化合物可抑制蛋白激酶（如 Src 家族激酶（如造血细胞激酶 (HCK)）、布鲁顿酪氨酸激酶 (BTK)），可用于治疗和/或预防增殖性疾病（如、骨髓增生异常、白血病、淋巴瘤（如瓦尔登斯特罗姆氏巨球蛋白血症））和诱导细胞（如恶性血细胞）凋亡。本公开还提供了包括或使用本文所述化合物的药物组合物、试剂盒、方法和用途。